Pyridoxine and depression: neuroendocrine aspects.
Plasma prolactin levels (PRL) were determined in 5 male depressed patients and in 5 controls, after injection of TRH (200 mg i.v.) (first phase), TRH following oral L-DOPA (500 mg) given 90 minutes before (second phase), TRH plus pyridoxine (300 mg i.v.) after same pretreatment with L-Dopa (third phase). L-Dopa induced a statistically significant suppression of TRH, caused PRL release; such suppression appears to be lower when TRH plus pyridoxine were administered simultaneously. PRL profile was not significantly different in the two groups.
D003866:Depressive Disorder / Q000097:blood* / Q000188:drug therapy; D004298:Dopamine / Q000502:physiology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D011388:Prolactin / Q000097:blood; D011736:Pyridoxine / Q000494:pharmacology*; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use*
D007980:Levodopa; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D011736:Pyridoxine; D004298:Dopamine